Market Overview on Bone Marrow Transplant Rejection - Pipeline Review, H2 2016
Bone Marrow Transplant Rejection - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Bone Marrow Transplant Rejection pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Bone Marrow Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bone Marrow Transplant Rejection and features dormant and discontinued projects.
Complete report available @ Bone Marrow Transplant Rejection - Pipeline Review, H2 2016
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape of Bone Marrow Transplant Rejection
- The report reviews pipeline therapeutics for Bone Marrow Transplant Rejection by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report reviews key players involved Bone Marrow Transplant Rejection therapeutics and enlists all their major and minor projects
- The report assesses Bone Marrow Transplant Rejection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Bone Marrow Transplant Rejection
- The report reviews pipeline therapeutics for Bone Marrow Transplant Rejection by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report reviews key players involved Bone Marrow Transplant Rejection therapeutics and enlists all their major and minor projects
- The report assesses Bone Marrow Transplant Rejection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Bone Marrow Transplant Rejection
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Bone Marrow Transplant Rejection
- Devise corrective measures for pipeline projects by understanding Bone Marrow Transplant Rejection pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Bone Marrow Transplant Rejection
- Devise corrective measures for pipeline projects by understanding Bone Marrow Transplant Rejection pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
AbbVie Inc AbGenomics International, Inc. Actelion Ltd Alexion Pharmaceuticals Inc Amunix Operating Inc. Apceth GmbH & Co. KG arGEN-X BV Athersys, Inc. Bellicum Pharmaceuticals, Inc. Bio-Cancer Treatment International Limited Biogen Inc Boryung Pharmaceutical Co., Ltd. Bristol-Myers Squibb Company Cantex Pharmaceuticals, Inc. Capricor Therapeutics, Inc. Cell Source, Inc. Cell2B S.A. CellECT Bio, Inc. Cleveland BioLabs, Inc. Compugen Ltd. Cynata Therapeutics Limited Cytodyn Inc. Dompe Farmaceutici S.p.A. Dr. Falk Pharma GmbH Escape Therapeutics, Inc. F. Hoffmann-La Roche Ltd. Fate Therapeutics, Inc. Generon (Shanghai) Corporation Ltd. Gilead Sciences, Inc. GlaxoSmithKline Plc Idera Pharmaceuticals, Inc. ImmuNext, Inc. Immunomedics, Inc. Incyte Corporation Kadmon Corporation, LLC Kamada Ltd. Kiadis Pharma N.V. Kymab Limited Kyorin Pharmaceutical Co., Ltd. MacroGenics, Inc. Mallinckrodt Plc Medsenic Mesoblast Limited Millennium Pharmaceuticals Inc Neopharm Ltd. Nohla Therapeutics Inc. Novartis AG OncoImmune, Inc. OSE Immunotherapeutics Pharmicell Co., Ltd. Pluristem Therapeutics Inc. REGiMMUNE Corporation Rigel Pharmaceuticals, Inc. Sarepta Therapeutics, Inc. Seattle Genetics, Inc. Seres Therapeutics, Inc. Sigmoid Pharma Limited Spherium Biomed S.L. Taiga Biotechnologies, Inc. Takeda Pharmaceutical Company Limited Targazyme, Inc. Therapix Biosciences Ltd Tobira Therapeutics, Inc. Vault Pharma Inc. Xenikos B.V. ZIOPHARM Oncology, Inc.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
posted by Reportstack @ 22:38
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home